Core Viewpoint - Zhijiang Biotech (688317.SH) forecasts a net profit attributable to shareholders of the parent company for 2025 to be between -32 million to -47 million yuan, indicating a significant loss compared to the previous year [1] Financial Performance - The expected net profit loss represents an increase in loss of 80.4621 million to 95.4621 million yuan year-on-year, reflecting a reduction in loss margin of 63.13% to 74.89% [1] Reasons for Performance Decline - The primary reasons for the company's performance decline include a decrease in sales of main products, the implementation of centralized procurement policies leading to price reductions, and an increase in the value-added tax rate for self-produced reagent products to 13%, resulting in decreased revenue [1] - Additional factors contributing to the loss include a decline in financial income and reduced foreign exchange gains [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, optimizing cost reduction and efficiency measures, and exploring potential opportunities to continuously improve product competitiveness and operational capabilities [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688331 证券简称：荣昌生物 公告编号：2026-005 港股代码：09995 港股简称：榮昌生物 荣昌生物制药（烟台）股份有限公司2022年及2023年A股限制性股票激励计划相关权益对应归属期归属 结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 2、2022年11月18日至2022年11月27日，公司对本次激励计划拟首次授予激励对象的姓名和职务在公司 内部进行了公示。在公示期内，公司监事会未收到与本次激励计划激励对象有关的任何异议。2022年12 月13日，公司于上海证券交易所网站（www.sse.com.cn）披露了《监事会关于公司2022年A股限制性股 票激励计划首次授予激励对象名单的公示情况说明及核查意见》（公告编号：2022-032）。 3、2022年12月13日，公司于上海证券交易所网站（www.sse.com.cn）披露了《荣昌生物制药（烟台） 股份有限公司关于独立董事公开征集委托投票权的公告》（公告编号：2022-031）， ...

（文章来源：每日经济新闻） 圣达生物（603079.SH）1月21日在投资者互动平台表示，公司始终将全球化发展作为驱动长期价值增 长的战略方向，目前包括维生素、生物保鲜及功能配料在内的主要产品均已形成面向欧洲等海外市场的 常态化出口布局，相关收入情况与公司整体国际化拓展节奏相适应。在销售模式上，公司秉持灵活多元 的销售策略，依据不同发展阶段和客户需求综合开展业务。 每经AI快讯，有投资者在投资者互动平台提问：2024 年，公司成功完成欧盟 CEP 注册，请问公司近年 是否存在向欧盟成员国出口或销售的相关业务？ ...

Core Viewpoint - Hualan Biological (002007.SZ) announced that its subsidiary Hualan Vaccine (301207) received approval from the National Medical Products Administration for clinical trials of a recombinant shingles vaccine, marking a significant step in the company's strategy for shingles prevention [1] Company Summary - Hualan Vaccine's recombinant shingles vaccine is designed to prevent shingles, but not primary varicella [1] - This vaccine represents an important development in Hualan Vaccine's portfolio within the shingles prevention market [1] Industry Summary - Currently, there are two shingles vaccine products available in the domestic market, indicating existing competition [1] - The aging population and increasing public health awareness are expected to drive significant market growth for shingles vaccines [1] - Vaccine development cycles are lengthy, and future progress and outcomes remain uncertain [1]

Group 1 - The biopharmaceutical sector increased by 0.19% on January 21, with Nearshore Protein leading the gains [1] - The Shanghai Composite Index closed at 4116.94, up 0.08%, while the Shenzhen Component Index closed at 14255.12, up 0.7% [1] - Key stocks in the biopharmaceutical sector showed significant price increases, with Nearshore Protein rising by 6.37% to a closing price of 48.76 [1] Group 2 - The biopharmaceutical sector experienced a net inflow of 77.04 million yuan from institutional investors, while retail investors saw a net outflow of 284 million yuan [2] - Major stocks like Watson Bio and Ganli Pharmaceutical attracted significant institutional investment, with net inflows of 64.45 million yuan and 55.25 million yuan, respectively [3] - Retail investors showed a negative trend in several stocks, with Watson Bio and Ganli Pharmaceutical experiencing net outflows of 33.30 million yuan and 39.14 million yuan, respectively [3]

南财智讯1月21日电，迈威生物公告，公司于2026年1月21日召开第二届董事会第二十七次会议，审议通 过了《关于继续使用部分暂时闲置募集资金进行现金管理的议案》。公司及全资子公司拟使用最高不超 过8.00亿元的暂时闲置募集资金进行现金管理，在额度及使用期限范围内资金可滚动使用，有效期自董 事会审议通过之日起12个月内有效。投资方向为购买安全性高、流动性好、有保本约定的投资产品，包 括但不限于结构性存款、通知存款、定期存款、大额存单、协定存款等。公司强调，该事项不会影响募 集资金投资项目进度和公司正常生产经营。 ...

Group 1 - Dongbao Biological experienced a stock price increase of 5.06%, reaching 6.44 CNY per share, with a trading volume of 142 million CNY and a turnover rate of 3.83%, resulting in a total market capitalization of 3.823 billion CNY [1] - The company, Baotou Dongbao Biological Technology Co., Ltd., is located in Baotou City, Inner Mongolia, and was established on March 12, 1997, with its listing date on July 6, 2011. Its main business involves the research, production, and sales of gelatin series products and low molecular weight collagen [1] - The revenue composition of Dongbao Biological includes capsule business at 54.13%, gelatin series products and by-products at 37.30%, collagen business at 7.81%, organic fertilizer business at 0.53%, and other supplementary products at 0.22% [1] Group 2 - Among the top circulating shareholders of Dongbao Biological, one fund from GF Fund Management, the GF Jufeng Mixed A (270005), entered the top ten shareholders in the third quarter, holding 4.5228 million shares, which is 0.77% of the circulating shares. The estimated floating profit today is approximately 1.4021 million CNY [2] - The GF Jufeng Mixed A fund was established on December 23, 2005, with a current scale of 3.366 billion CNY. Year-to-date returns are 11.92%, ranking 540 out of 8844 in its category; the one-year return is 70.13%, ranking 640 out of 8091; and since inception, the return is 556.36% [2]

Group 1 - The company expects a net loss attributable to shareholders of 220 million to 280 million yuan for the fiscal year 2025, representing a year-on-year decrease of 194.79% to 220.64% [1] - The expected net loss excluding non-recurring items is projected to be between 240 million to 300 million yuan, with a year-on-year decrease of 204.43% to 230.54% [1] - For the fiscal year 2024, the company anticipates a net profit attributable to shareholders of 232 million yuan and a net profit excluding non-recurring items of 230 million yuan, with earnings per share of 0.56 yuan [1] Group 2 - The sales revenue of the company's herpes zoster live attenuated vaccine has declined due to factors such as the awareness of the disease among potential vaccine recipients and their willingness to receive the vaccine [1] - Some confirmed revenue from the herpes zoster vaccine could not be realized due to expiration before vaccination, leading to returns [1] - The unit price of the herpes zoster vaccine has decreased, contributing to the overall decline in sales revenue year-on-year [1]

近日，热景生物发布公告称，预计2025年年度实现营业收入4亿元至4.2亿元，与上年同期相比，同比减少17.79%至 21.71%。 此外，其他联营企业在生物创新药领域的研发投入也导致投资损失扩大，进一步影响了公司净利润。 （热景生物公告） 预计归母净利润约亏损2.1亿元至2.3亿元，与上年同期相比，亏损增加9.94%至20.42%。此外，预计归母净利润扣除非 经常性损益后约亏损2.5亿元至2.7亿元。 公告中提到，业绩下滑的主要原因包括行业政策影响导致价格下降及需求减少，以及税收政策调整对综合毛利率的影 响。同时，公司对联营企业舜景医药增资，使其成为控股子公司，研发费用大幅增加，对净利润产生较大影响。 ...

Group 1: Macroeconomic Insights - In 2025, China's GDP reached 140.2 trillion yuan, with a nominal growth of 5% year-on-year, surpassing global averages and achieving significant milestones during the "14th Five-Year Plan" [4][5][12] - The economic growth rate showed a pattern of high growth in the first half of the year, with quarterly GDP growth rates of 5.4%, 5.2%, 4.8%, and 4.5% respectively [4][5] - The contribution of net exports to economic growth was 32.7%, indicating strong external demand despite trade tensions [5][12] Group 2: Consumption Trends - Retail sales of consumer goods increased by 3.7% year-on-year, with final consumption contributing approximately 52% to economic growth [6][7] - The "trade-in" policy significantly boosted sales in various categories, with retail sales of home appliances and audio-visual equipment rising by 11% and furniture by 14.6% [6][7] - Service consumption grew rapidly, with a 5.5% increase in service retail sales, highlighting a shift towards experiential and health-related spending [7][8] Group 3: Investment Dynamics - Fixed asset investment in 2025 was 48.5 trillion yuan, a decrease of 3.8% year-on-year, with infrastructure investment down by 2.2% and manufacturing investment up by 0.6% [9][10] - High-tech industry investment saw significant growth, with information services up by 28.4% and aerospace manufacturing by 16.9% [11] - The government plans to increase central budget investment in 2026, which is expected to support overall investment recovery [10][11] Group 4: Trade and Export Performance - In 2025, China's total foreign trade reached 45.47 trillion yuan, with exports growing by 6.1% to 26.99 trillion yuan, marking a historical high [12][13] - The structure of exports has shifted towards high-value-added products, with mechanical and electrical products accounting for 61% of total exports [13][14] - Trade dependency on the U.S. has decreased, with exports to the U.S. dropping to 11.1% of total exports in 2025 [14] Group 5: Automotive Industry Developments - The automotive sector saw a weekly increase in stock performance, with the automotive index rising by 0.5% [15][16] - The introduction of the "price commitment" mechanism for electric vehicles is expected to stabilize sales in Europe and promote high-end and localized production [16][18] - Several provinces have opened channels for 2026 vehicle replacement subsidies, indicating government support for the automotive market [17][18] Group 6: AI and Pharmaceutical Innovations - The collaboration between NVIDIA and Eli Lilly aims to leverage AI in drug discovery, with a projected investment of up to $1 billion over five years [24] - AI is expected to transform traditional drug development processes, shifting from labor-intensive methods to data-driven approaches [24] - The pharmaceutical sector has shown resilience, with a 7.08% return in early 2026, despite recent adjustments in stock prices [25]